Two oral GLP-1 medications for weight management have now been approved in the United States, removing the injection from the decision for the first time. The FDA approved a once-daily oral semaglutide tablet for chronic weight management in December 2025, the first oral GLP-1 cleared for that use, with a launch in early January. On April 1 of this year, it approved orforglipron, a nonpeptide oral GLP-1 receptor agonist marketed as Foundayo, for adults with obesity or overweight with at least one weight-related condition. Since then, it has issued three major rounds of letters largely aimed at telehealth companies marketing compounded GLP-1 products, including a batch of thirty letters announced in March and another wave of twenty-five letters in mid-June. Are compounded GLP-1 products the same as branded ones?